Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence
Background The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement ther...
Saved in:
| Published in: | BMC public health Vol. 10; no. 1; p. 680 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
09.11.2010
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1471-2458, 1471-2458 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows:
IAdherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype).
II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype.
Methods/Design
An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups:
i. NRT oral dose tailored by DNA analysis (
OPRM1
gene) (genotype), or
ii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)
The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples
t
-test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II).
Discussion
This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed.
Trial details
Funder: Medical Research Council (MRC)
Grant number: G0500274
ISRCTN: 14352545
Date trial stated: June 2007
Expected end date: December 2009
Expected reporting date: December 2010 |
|---|---|
| AbstractList | The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups: This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. Abstract Background: The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: I Adherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype). II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype. Methods/Design: An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups: i. NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), or ii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype) The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t -test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II). Discussion: This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. Trial details: Funder: Medical Research Council (MRC) Grant number: G0500274 ISRCTN: 14352545 Date trial stated: June 2007 Expected end date: December 2009 Expected reporting date: December 2010 Background The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: Methods/Design An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups: The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t-test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II). Discussion This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. Trial details Funder: Medical Research Council (MRC) Grant number: G0500274 ISRCTN: 14352545 Date trial stated: June 2007 Expected end date: December 2009 Expected reporting date: December 2010 The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: I Adherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype). II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype.BACKGROUNDThe behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: I Adherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype). II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype.An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups:i. NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), orii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t-test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II).METHODS/DESIGNAn open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups:i. NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), orii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t-test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II).This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. TRIAL DETAILS: Funder: Medical Research Council (MRC)Grant number: G0500274. ISRCTN: 14352545. Date trial stated: June 2007. Expected end date: December 2009. Expected reporting date: December 2010.DISCUSSIONThis is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. TRIAL DETAILS: Funder: Medical Research Council (MRC)Grant number: G0500274. ISRCTN: 14352545. Date trial stated: June 2007. Expected end date: December 2009. Expected reporting date: December 2010. Abstract Background The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: IAdherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype). II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype. Methods/Design An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups: i. NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), or ii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype) The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t-test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II). Discussion This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. Trial details Funder: Medical Research Council (MRC) Grant number: G0500274 ISRCTN: 14352545 Date trial stated: June 2007 Expected end date: December 2009 Expected reporting date: December 2010 Background The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: IAdherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype). II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype. Methods/Design An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups: i. NRT oral dose tailored by DNA analysis ( OPRM1 gene) (genotype), or ii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype) The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t -test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II). Discussion This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. Trial details Funder: Medical Research Council (MRC) Grant number: G0500274 ISRCTN: 14352545 Date trial stated: June 2007 Expected end date: December 2009 Expected reporting date: December 2010 The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may increase adherence to this medication. The objective of this trial is to estimate the impact upon adherence to nicotine replacement therapy (NRT) of informing smokers that their oral dose of NRT has been tailored to a DNA analysis. Hypotheses to be tested are as follows: I Adherence to NRT is greater among smokers informed that their oral dose of NRT is tailored to an analysis of DNA (genotype), compared to one tailored to nicotine dependence questionnaire score (phenotype). II Amongst smokers who fail to quit at six months, motivation to make another quit attempt is lower when informed that their oral dose of NRT was tailored to genotype rather than phenotype. An open label, parallel groups randomised trial in which 630 adult smokers (smoking 10 or more cigarettes daily) using National Health Service (NHS) stop smoking services in primary care are randomly allocated to one of two groups:i. NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype), orii. NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)The primary outcome is proportion of prescribed NRT consumed in the first 28 days following an initial quit attempt, with the secondary outcome being motivation to make another quit attempt, amongst smokers not abstinent at six months. Other outcomes include adherence to NRT in the first seven days and biochemically validated smoking abstinence at six months. The primary outcome will be collected on 630 smokers allowing sufficient power to detect a 7.5% difference in mean proportion of NRT consumed using a two-tailed test at the 5% level of significance between groups. The proportion of all NRT consumed in the first four weeks of quitting will be compared between arms using an independent samples t-test and by estimating the 95% confidence interval for observed between-arm difference in mean NRT consumption (Hypothesis I). Motivation to make another quit attempt will be compared between arms in those failing to quit by six months (Hypothesis II). This is the first clinical trial evaluating the behavioural impact on adherence of prescribing medication using genetic rather than phenotypic information. Specific issues regarding the choice of design for trials of interventions of this kind are discussed. TRIAL DETAILS: Funder: Medical Research Council (MRC)Grant number: G0500274. ISRCTN: 14352545. Date trial stated: June 2007. Expected end date: December 2009. Expected reporting date: December 2010. |
| ArticleNumber | 680 |
| Audience | Academic |
| Author | Prevost, A Toby Willis, Thomas A Wright, Alison J Whitwell, Sophia Hollands, Gareth J Sutton, Stephen Kinmonth, Ann Louise Marteau, Theresa M Hill, Chloe Johnstone, Elaine C Munafò, Marcus R Crockett, Rachel A Aveyard, Paul Armstrong, David |
| AuthorAffiliation | 3 Primary Care Clinical Sciences, University of Birmingham, Birmingham, B15 2TT, UK 2 Department of Experimental Psychology, 12a Priory Road, University of Bristol, Bristol, BS8 1TU, UK 4 University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, Old Road Campus, Headington, Oxford OX3 7DQ, UK 6 University of Cambridge Department of Public Health and Primary Care, Forvie Site, Robinson Way, Cambridge, CB2 0SR, UK 1 King's College London, Psychology Department (at Guy's), Health Psychology Section, 5th Floor Bermondsey Wing, Guy's Campus, London SE1 9RT, UK 5 King's College London, Department of Primary Care and Public Health Sciences, 5th Floor Capital House, 42 Weston Street, London SE1 3QD, UK |
| AuthorAffiliation_xml | – name: 4 University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, Old Road Campus, Headington, Oxford OX3 7DQ, UK – name: 1 King's College London, Psychology Department (at Guy's), Health Psychology Section, 5th Floor Bermondsey Wing, Guy's Campus, London SE1 9RT, UK – name: 3 Primary Care Clinical Sciences, University of Birmingham, Birmingham, B15 2TT, UK – name: 6 University of Cambridge Department of Public Health and Primary Care, Forvie Site, Robinson Way, Cambridge, CB2 0SR, UK – name: 2 Department of Experimental Psychology, 12a Priory Road, University of Bristol, Bristol, BS8 1TU, UK – name: 5 King's College London, Department of Primary Care and Public Health Sciences, 5th Floor Capital House, 42 Weston Street, London SE1 3QD, UK |
| Author_xml | – sequence: 1 givenname: Theresa M surname: Marteau fullname: Marteau, Theresa M email: theresa.marteau@kcl.ac.uk organization: King's College London, Psychology Department (at Guy's), Health Psychology Section – sequence: 2 givenname: Marcus R surname: Munafò fullname: Munafò, Marcus R organization: Department of Experimental Psychology, University of Bristol – sequence: 3 givenname: Paul surname: Aveyard fullname: Aveyard, Paul organization: Primary Care Clinical Sciences, University of Birmingham – sequence: 4 givenname: Chloe surname: Hill fullname: Hill, Chloe organization: King's College London, Psychology Department (at Guy's), Health Psychology Section – sequence: 5 givenname: Sophia surname: Whitwell fullname: Whitwell, Sophia organization: King's College London, Psychology Department (at Guy's), Health Psychology Section – sequence: 6 givenname: Thomas A surname: Willis fullname: Willis, Thomas A organization: King's College London, Psychology Department (at Guy's), Health Psychology Section – sequence: 7 givenname: Rachel A surname: Crockett fullname: Crockett, Rachel A organization: King's College London, Psychology Department (at Guy's), Health Psychology Section – sequence: 8 givenname: Gareth J surname: Hollands fullname: Hollands, Gareth J organization: King's College London, Psychology Department (at Guy's), Health Psychology Section – sequence: 9 givenname: Elaine C surname: Johnstone fullname: Johnstone, Elaine C organization: Department of Clinical Pharmacology, Old Road Campus Research Building, University of Oxford – sequence: 10 givenname: Alison J surname: Wright fullname: Wright, Alison J organization: Department of Primary Care and Public Health Sciences, King's College London – sequence: 11 givenname: A Toby surname: Prevost fullname: Prevost, A Toby organization: Department of Primary Care and Public Health Sciences, King's College London – sequence: 12 givenname: David surname: Armstrong fullname: Armstrong, David organization: Department of Primary Care and Public Health Sciences, King's College London – sequence: 13 givenname: Stephen surname: Sutton fullname: Sutton, Stephen organization: University of Cambridge Department of Public Health and Primary Care – sequence: 14 givenname: Ann Louise surname: Kinmonth fullname: Kinmonth, Ann Louise organization: University of Cambridge Department of Public Health and Primary Care |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21062464$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhSNURB-wZ4UsWLCa4kfixF1UqioelSrBol1bjn099Sixg-1Bmv_DD8WZKaVTAYqUWNfnfNe-OcfVgQ8equo1waeEdPwDqVuyoHXTLQhe8A4_q44eSgeP1ofVcUorjEnbNfRFdUgJ5rTm9VH18yY6NaBvMeSgw3CGbpPzS7QEH_JmApQDysoNIaIpQtLR9fN2sMg7HbLzgCJMg9Iwgs8o30FU0-YMKRSVN2F0CQzSwecYhqEs87abSgnSto8bJ6XzzNNhHNcFqrILHq2n8lKm4MBreFk9t2pI8Or-e1Ldfvp4c_llcf3189XlxfVCN6LNC6s5bhXXjLCaCtpjbQGIxl0ruOXWNMK2hNTWME5sY1hPCLV9R1nTcWOFYSfV1Y5rglrJKbpRxY0MysltIcSlVDE7PYCkTFFNWyG40rVgQvRG1XVjoQdrjZlZ5zvWtO5HMLqMJ6phD7q_492dXIYfkhYma3EBvL8HxPB9DSnLMk0Nw6A8hHWSHWkEbxhri_LtE-UqrKMvk5ICUyJY19IiercTLVU5vvM2lK56RsoLWjMmOlFgJ9XpX1TlMTCWH-7BulLfM7x5fM2H-_1OWBHgnUDHkFIE-yAhWM4hlnNK5ZzSuVJCXCz8iUW7vM1FOYwb_mckO2MqPfwS4p9B_NPzC8rmB-w |
| CitedBy_id | crossref_primary_10_1111_j_1360_0443_2012_03957_x crossref_primary_10_1186_1747_597X_6_17 crossref_primary_10_1016_j_molmed_2017_12_001 crossref_primary_10_1093_ntr_ntt010 crossref_primary_10_1371_journal_pone_0035249 crossref_primary_10_1016_j_jsat_2021_108591 crossref_primary_10_1016_j_drugalcdep_2015_03_035 crossref_primary_10_1016_j_beem_2011_11_004 crossref_primary_10_1016_j_healthplace_2014_01_008 crossref_primary_10_1186_1745_6215_15_296 crossref_primary_10_1192_bjp_bp_112_114389 |
| Cites_doi | 10.1136/tc.12.2.227 10.1038/sj.tpj.6500432 10.1093/her/cyp069 10.1111/j.1360-0443.1991.tb02637.x 10.1111/j.1360-0443.2007.01791.x 10.1073/pnas.95.16.9608 10.1038/464674a 10.1007/s11920-006-0016-0 10.1111/j.1360-0443.1989.tb03474.x 10.1136/thx.2006.071837 10.1136/bmj.39252.591806.47 10.1074/jbc.M504942200 10.1023/A:1015818532390 10.1080/14622200600670397 10.1097/01.GIM.0000068986.03217.BB 10.1016/j.amepre.2007.09.006 10.1111/j.1360-0443.2004.00995.x 10.1038/nature01626 10.1023/A:1023513310243 10.1016/j.socscimed.2005.08.005 10.1007/s11920-007-0045-3 10.1046/j.1360-0443.2003.00295.x 10.1002/ajmg.a.30102 10.1016/j.clinthera.2008.07.019 10.1176/appi.ps.57.3.382 10.1074/jbc.M006352200 10.1093/nar/16.3.1215 10.1111/j.1471-4159.2004.02340.x 10.1016/S0376-8716(98)00124-0 10.1016/j.cnur.2007.10.006 10.1080/1462220031000070552 10.1517/14622416.6.3.211 10.1038/sj.tpj.6500238 10.1002/14651858.CD000146.pub2 10.1002/14651858.CD000146.pub3 |
| ContentType | Journal Article |
| Copyright | Marteau et al; licensee BioMed Central Ltd. 2010 COPYRIGHT 2010 BioMed Central Ltd. 2010 Marteau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2010 Marteau et al; licensee BioMed Central Ltd. 2010 Marteau et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Marteau et al; licensee BioMed Central Ltd. 2010 – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: 2010 Marteau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2010 Marteau et al; licensee BioMed Central Ltd. 2010 Marteau et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T2 7X7 7XB 88E 8C1 8FE 8FG 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA AN0 ATCPS AZQEC BENPR BGLVJ BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V M0S M1P M7S PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 5PM DOA |
| DOI | 10.1186/1471-2458-10-680 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Materials Science & Engineering ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database (Proquest) Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection ProQuest Health & Medical Collection Medical Database Engineering Database Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Engineering Database ProQuest Public Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1471-2458 |
| EndPage | 680 |
| ExternalDocumentID | oai_doaj_org_article_23a2c27996ac49399bda445febeffddd PMC2996370 2503029831 A243398953 21062464 10_1186_1471_2458_10_680 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | England United Kingdom |
| GeographicLocations_xml | – name: England – name: United Kingdom |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G0200391 – fundername: Medical Research Council grantid: G0500274 – fundername: Medical Research Council grantid: G0500267 |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 2XV 4.4 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C1A C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 L6V M1P M48 M7S M~E O5R O5S OK1 OVT P2P PATMY PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PYCSY RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7T2 7XB 8FK AZQEC C1K DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c597t-fc607a6c3134292b0cfee1c08796f6fd59f7114fd361f5d3b112fb823586df9d3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000284893300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2458 |
| IngestDate | Fri Oct 03 12:44:49 EDT 2025 Tue Nov 04 01:51:43 EST 2025 Mon Sep 29 06:34:58 EDT 2025 Sat Oct 11 05:42:31 EDT 2025 Tue Nov 11 10:37:54 EST 2025 Sat Nov 29 10:23:45 EST 2025 Mon Jul 21 06:04:12 EDT 2025 Sat Nov 29 06:22:13 EST 2025 Tue Nov 18 20:25:49 EST 2025 Sat Sep 06 07:28:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | National Health Service Nicotine Dependence Nicotine Replacement Therapy Nicotine Smoking Cessation |
| Language | English |
| License | http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c597t-fc607a6c3134292b0cfee1c08796f6fd59f7114fd361f5d3b112fb823586df9d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1186/1471-2458-10-680 |
| PMID | 21062464 |
| PQID | 902193872 |
| PQPubID | 44782 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_23a2c27996ac49399bda445febeffddd pubmedcentral_primary_oai_pubmedcentral_nih_gov_2996370 proquest_miscellaneous_815965337 proquest_journals_902193872 gale_infotracmisc_A243398953 gale_infotracacademiconefile_A243398953 pubmed_primary_21062464 crossref_primary_10_1186_1471_2458_10_680 crossref_citationtrail_10_1186_1471_2458_10_680 springer_journals_10_1186_1471_2458_10_680 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-11-09 |
| PublicationDateYYYYMMDD | 2010-11-09 |
| PublicationDate_xml | – month: 11 year: 2010 text: 2010-11-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC public health |
| PublicationTitleAbbrev | BMC Public Health |
| PublicationTitleAlternate | BMC Public Health |
| PublicationYear | 2010 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | Iselin, Addis (CR20) 2003; 27 West, Hajek, Stead, Stapleton (CR40) 2005; 100 Bond, LaForge, Tian, Melia, Zhang, Borg, Gong, Schluger, Strong, Leal, Tischfield, Kreek, Yu (CR14) 1998; 95 Shiloh, Rashuk-Rosenthal, Benyamini (CR29) 2002; 25 Marteau, Weinman (CR19) 2006; 62 Miller, Dykes, Potesky (CR30) 1988; 6 Gramling, Nash, Siren, Culpepper (CR5) 2003; 5 Heatherton, Kozlowski, Frecker, Fagerstrom (CR36) 1991; 86 Beyer, Koch, Schroder, Schulz, Hollt (CR16) 2004; 89 McBride, Bepler, Lipkus, Lyna, Samsa, Albright, Datta, Rimer (CR24) 2002; 11 Lerman, Schnoll, Munafò (CR10) 2007; 33 Munafò, Elliot, Murphy, Walton, Johnstone (CR18) 2007; 7 CR33 CR32 Li, Cheng, Ma, Swan (CR8) 2003; 98 Marteau, Senior, Humphries, Bobrow, Cranston, Crook, Day, Fernandez, Horne, Iversen, Jackson, Lynas, Middleton-Price, Savine, Sikorski, Watson, Weinman, Wierzbicki, Wray (CR21) 2004; 128A Mooney, Leventhal, Hatsukami (CR1) 2006; 8 Phelan, Yang, Cruz-Rojas (CR22) 2006; 57 Lerman, Wileyto, Patterson, Rukstalis, Audrain-McGovern, Restine, Shields, Kaufmann, Redden, Benowitz, Berrettini (CR17) 2004; 4 (CR35) 2010 Shiffman (CR26) 2007; 102 Aveyard, Brown, Saunders, Alexander, Johnstone, Munafò, Murphy (CR37) 2007; 62 Zhang, Wang, Johnson, Papp, Sadee (CR13) 2005; 280 Collins (CR3) 2010; 464 Aveyard, West (CR31) 2007; 335 Collins, Green, Guttmacher, Guyer (CR4) 2003; 422 Munafò, Shields, Berrettini, Patterson, Lerman (CR12) 2005; 6 Wright, Weinman, Marteau (CR23) 2003; 12 Wu, Moser, Lennie, Burkhart (CR25) 2008; 43 CR28 Li (CR7) 2006; 8 Shiffman (CR27) 2008; 30 Bansal-Travers, Cummings, Hyland, Brown, Celestino (CR2) 2010; 25 Hughes, Keely, Niaura, Ossip-Klein, Richmond, Swan (CR39) 2003; 5 Alterman, Gariti, Cook, Cnaan (CR41) 1999; 53 Chen, Chaiken, Chaiken, Trope (CR6) 1999 Schnoll, Johnson, Lerman (CR9) 2007; 9 (CR38) 2002 Munafò, Lerman, Niaura, Shields, Swan (CR11) 2005; 7 Befort, Filliol, Decaillot, Gaveriaux-Ruff, Hoehe, Kieffer (CR15) 2001; 276 Hajek (CR34) 1989; 84 S Shiloh (2591_CR29) 2002; 25 FS Collins (2591_CR4) 2003; 422 2591_CR33 JR Hughes (2591_CR39) 2003; 5 2591_CR32 ME Mooney (2591_CR1) 2006; 8 M Bansal-Travers (2591_CR2) 2010; 25 RA Schnoll (2591_CR9) 2007; 9 A Beyer (2591_CR16) 2004; 89 P Aveyard (2591_CR37) 2007; 62 S Chen (2591_CR6) 1999 MD Li (2591_CR7) 2006; 8 F Collins (2591_CR3) 2010; 464 National Institute for Health and Clinical Excellence (2591_CR38) 2002 S Shiffman (2591_CR26) 2007; 102 P Aveyard (2591_CR31) 2007; 335 MR Munafò (2591_CR12) 2005; 6 MR Munafò (2591_CR18) 2007; 7 TM Marteau (2591_CR19) 2006; 62 C Lerman (2591_CR10) 2007; 33 JC Phelan (2591_CR22) 2006; 57 R West (2591_CR40) 2005; 100 AI Alterman (2591_CR41) 1999; 53 Y Zhang (2591_CR13) 2005; 280 AJ Wright (2591_CR23) 2003; 12 C Lerman (2591_CR17) 2004; 4 MG Iselin (2591_CR20) 2003; 27 P Hajek (2591_CR34) 1989; 84 S Shiffman (2591_CR27) 2008; 30 MD Li (2591_CR8) 2003; 98 2591_CR28 CM McBride (2591_CR24) 2002; 11 NCSCT (NHS Centre for Smoking Cessation and Training) (2591_CR35) 2010 T Marteau (2591_CR21) 2004; 128A R Gramling (2591_CR5) 2003; 5 C Bond (2591_CR14) 1998; 95 SA Miller (2591_CR30) 1988; 6 TF Heatherton (2591_CR36) 1991; 86 JR Wu (2591_CR25) 2008; 43 K Befort (2591_CR15) 2001; 276 MR Munafò (2591_CR11) 2005; 7 |
| References_xml | – volume: 12 start-page: 227 year: 2003 end-page: 230 ident: CR23 article-title: The impact of learning of a genetic predisposition to nicotine dependence: an analogue study publication-title: Tobacco Control doi: 10.1136/tc.12.2.227 – volume: 7 start-page: 353 year: 2007 end-page: 361 ident: CR18 article-title: Association of the mu-opioid receptor gene with smoking cessation publication-title: The Pharmacogenomics Journal doi: 10.1038/sj.tpj.6500432 – volume: 25 start-page: 678 year: 2010 end-page: 686 ident: CR2 article-title: Educating smokers about their cigarettes and nicotine medications publication-title: Health Education Research doi: 10.1093/her/cyp069 – volume: 86 start-page: 119 year: 1991 end-page: 127 ident: CR36 article-title: The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire publication-title: British Journal of Addiction doi: 10.1111/j.1360-0443.1991.tb02637.x – volume: 102 start-page: 809 year: 2007 end-page: 814 ident: CR26 article-title: Use of more nicotine lozenges leads to better success in quitting smoking publication-title: Addiction doi: 10.1111/j.1360-0443.2007.01791.x – volume: 95 start-page: 9608 year: 1998 end-page: 9613 ident: CR14 article-title: Single nucleotide polymorphism in the human mu-opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.16.9608 – volume: 464 start-page: 674 year: 2010 end-page: 5 ident: CR3 article-title: Has the revolution arrived? publication-title: Nature doi: 10.1038/464674a – volume: 8 start-page: 158 year: 2006 end-page: 164 ident: CR7 article-title: The genetics of nicotine dependence publication-title: Curr Psychiatry Rep doi: 10.1007/s11920-006-0016-0 – volume: 84 start-page: 591 year: 1989 end-page: 598 ident: CR34 article-title: Withdrawal-oriented Therapy for Smokers publication-title: British Journal of Addiction doi: 10.1111/j.1360-0443.1989.tb03474.x – volume: 62 start-page: 898 year: 2007 end-page: 903 ident: CR37 article-title: Weekly versus basic smoking cessation support in primary care: a randomised controlled trial publication-title: Thorax doi: 10.1136/thx.2006.071837 – volume: 335 start-page: 37 issue: 7609 year: 2007 end-page: 41 ident: CR31 article-title: Managing smoking cessation publication-title: British Medical Journal doi: 10.1136/bmj.39252.591806.47 – year: 2010 ident: CR35 publication-title: Learning Outcomes for Training Stop Smoking Specialists – ident: CR33 – volume: 280 start-page: 32618 year: 2005 end-page: 32624 ident: CR13 article-title: Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G publication-title: J Biol Chem doi: 10.1074/jbc.M504942200 – start-page: 73 year: 1999 end-page: 96 ident: CR6 article-title: The heuristic-systematic model in its broader context publication-title: Dual process theories in social psychology – volume: 25 start-page: 373 year: 2002 end-page: 394 ident: CR29 article-title: Illness causal attributions: an exploratory study of their structure and associations with other illness cognitions and perceptions of control publication-title: J Behav Med doi: 10.1023/A:1015818532390 – volume: 8 start-page: 435 year: 2006 end-page: 446 ident: CR1 article-title: Attitudes and knowledge about nicotine and nicotine replacement therapy publication-title: Nicotine & Tobacco Research doi: 10.1080/14622200600670397 – volume: 7 start-page: 202 year: 2005 end-page: 208 ident: CR11 article-title: Smoking cessation treatment: Pharmacogenetic assessment publication-title: Current Opinion in Molecular Therapeutics – volume: 5 start-page: 172 year: 2003 end-page: 175 ident: CR5 article-title: Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk publication-title: Genetics in Medicine doi: 10.1097/01.GIM.0000068986.03217.BB – volume: 33 start-page: S398 year: 2007 end-page: S405 ident: CR10 article-title: Genetics and smoking cessation: Improving outcome in patients at risk publication-title: American Journal of Preventive Medicine doi: 10.1016/j.amepre.2007.09.006 – volume: 100 start-page: 299 year: 2005 end-page: 303 ident: CR40 article-title: Outcome criteria in smoking cessation trials: proposal for a common standard publication-title: Addiction doi: 10.1111/j.1360-0443.2004.00995.x – volume: 422 start-page: 835 issue: 6934 year: 2003 end-page: 847 ident: CR4 article-title: A vision for the future of genomics research: A blueprint for the genomic era publication-title: Nature doi: 10.1038/nature01626 – volume: 27 start-page: 205 year: 2003 end-page: 222 ident: CR20 article-title: Effects of etiology on perceived helpfulness of treatments for depression publication-title: Cognitive therapy and research doi: 10.1023/A:1023513310243 – volume: 62 start-page: 1360 issue: 6 year: 2006 end-page: 1368 ident: CR19 article-title: Self-regulation and the behavioural response to DNA risk information: A theoretical analysis and framework for future research publication-title: Social Science & Medicine doi: 10.1016/j.socscimed.2005.08.005 – year: 2002 ident: CR38 publication-title: Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation – volume: 9 start-page: 349 year: 2007 end-page: 357 ident: CR9 article-title: Genetics and smoking behavior publication-title: Curr Psychiatry Rep doi: 10.1007/s11920-007-0045-3 – volume: 11 start-page: 521 year: 2002 end-page: 528 ident: CR24 article-title: Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income publication-title: Cancer Epidemiology, Biomarkers & Prevention – volume: 98 start-page: 23 year: 2003 end-page: 31 ident: CR8 article-title: A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins publication-title: Addiction doi: 10.1046/j.1360-0443.2003.00295.x – volume: 128A start-page: 285 year: 2004 end-page: 293 ident: CR21 article-title: Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial publication-title: American Journal of Medical Genetics doi: 10.1002/ajmg.a.30102 – ident: CR32 – volume: 30 start-page: 1461 issue: 8 year: 2008 end-page: 1475 ident: CR27 article-title: Effect of nicotine lozenges on affective smoking withdrawal symptoms: Secondary analysis of a randomized, double-blind, placebo-controlled clinical trial publication-title: Clinical Therapeutics doi: 10.1016/j.clinthera.2008.07.019 – volume: 57 start-page: 382 year: 2006 end-page: 387 ident: CR22 article-title: Effects of attributing serious mental illnesses to genetic causes on orientations to treatment publication-title: Psychiatric Services doi: 10.1176/appi.ps.57.3.382 – volume: 276 start-page: 3130 year: 2001 end-page: 3137 ident: CR15 article-title: A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling publication-title: J Biol Chem doi: 10.1074/jbc.M006352200 – volume: 6 start-page: 1215 issue: 3 year: 1988 ident: CR30 article-title: A simple salting out procedure for extracting DNA from human nucleated cells publication-title: Nucleic Acids Research doi: 10.1093/nar/16.3.1215 – ident: CR28 – volume: 89 start-page: 553 year: 2004 end-page: 560 ident: CR16 article-title: Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human muopioid receptor publication-title: J Neurochem doi: 10.1111/j.1471-4159.2004.02340.x – volume: 53 start-page: 159 year: 1999 end-page: 165 ident: CR41 article-title: Nicodermal patch adherence and its correlates publication-title: Drug & alcohol dependence doi: 10.1016/S0376-8716(98)00124-0 – volume: 43 start-page: 133 year: 2008 end-page: 153 ident: CR25 article-title: Medication adherence in patients who have heart failure: A review of the literature publication-title: Nursing Clinics of North America doi: 10.1016/j.cnur.2007.10.006 – volume: 5 start-page: 13 year: 2003 end-page: 25 ident: CR39 article-title: Measures of abstinence in clinical trials: issues and recommendations publication-title: Nicotine &Tobacco Research doi: 10.1080/1462220031000070552 – volume: 6 start-page: 211 year: 2005 end-page: 223 ident: CR12 article-title: Pharmacogenetics and nicotine addiction treatment publication-title: Pharmacogenomics doi: 10.1517/14622416.6.3.211 – volume: 4 start-page: 184 year: 2004 end-page: 192 ident: CR17 article-title: The functional mu opioid receptor ( ) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial publication-title: Pharmacogenomics Journal doi: 10.1038/sj.tpj.6500238 – volume: 9 start-page: 349 year: 2007 ident: 2591_CR9 publication-title: Curr Psychiatry Rep doi: 10.1007/s11920-007-0045-3 – volume: 43 start-page: 133 year: 2008 ident: 2591_CR25 publication-title: Nursing Clinics of North America doi: 10.1016/j.cnur.2007.10.006 – volume: 464 start-page: 674 year: 2010 ident: 2591_CR3 publication-title: Nature doi: 10.1038/464674a – volume-title: Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation year: 2002 ident: 2591_CR38 – volume: 33 start-page: S398 year: 2007 ident: 2591_CR10 publication-title: American Journal of Preventive Medicine doi: 10.1016/j.amepre.2007.09.006 – volume: 86 start-page: 119 year: 1991 ident: 2591_CR36 publication-title: British Journal of Addiction doi: 10.1111/j.1360-0443.1991.tb02637.x – volume: 100 start-page: 299 year: 2005 ident: 2591_CR40 publication-title: Addiction doi: 10.1111/j.1360-0443.2004.00995.x – volume: 95 start-page: 9608 year: 1998 ident: 2591_CR14 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.16.9608 – volume: 12 start-page: 227 year: 2003 ident: 2591_CR23 publication-title: Tobacco Control doi: 10.1136/tc.12.2.227 – volume: 4 start-page: 184 year: 2004 ident: 2591_CR17 publication-title: Pharmacogenomics Journal doi: 10.1038/sj.tpj.6500238 – volume: 62 start-page: 1360 issue: 6 year: 2006 ident: 2591_CR19 publication-title: Social Science & Medicine doi: 10.1016/j.socscimed.2005.08.005 – volume: 89 start-page: 553 year: 2004 ident: 2591_CR16 publication-title: J Neurochem doi: 10.1111/j.1471-4159.2004.02340.x – volume: 8 start-page: 158 year: 2006 ident: 2591_CR7 publication-title: Curr Psychiatry Rep doi: 10.1007/s11920-006-0016-0 – volume: 27 start-page: 205 year: 2003 ident: 2591_CR20 publication-title: Cognitive therapy and research doi: 10.1023/A:1023513310243 – volume-title: Learning Outcomes for Training Stop Smoking Specialists year: 2010 ident: 2591_CR35 – volume: 53 start-page: 159 year: 1999 ident: 2591_CR41 publication-title: Drug & alcohol dependence doi: 10.1016/S0376-8716(98)00124-0 – volume: 8 start-page: 435 year: 2006 ident: 2591_CR1 publication-title: Nicotine & Tobacco Research doi: 10.1080/14622200600670397 – volume: 276 start-page: 3130 year: 2001 ident: 2591_CR15 publication-title: J Biol Chem doi: 10.1074/jbc.M006352200 – volume: 128A start-page: 285 year: 2004 ident: 2591_CR21 publication-title: American Journal of Medical Genetics doi: 10.1002/ajmg.a.30102 – volume: 6 start-page: 1215 issue: 3 year: 1988 ident: 2591_CR30 publication-title: Nucleic Acids Research doi: 10.1093/nar/16.3.1215 – volume: 30 start-page: 1461 issue: 8 year: 2008 ident: 2591_CR27 publication-title: Clinical Therapeutics doi: 10.1016/j.clinthera.2008.07.019 – ident: 2591_CR28 – start-page: 73 volume-title: Dual process theories in social psychology year: 1999 ident: 2591_CR6 – volume: 7 start-page: 202 year: 2005 ident: 2591_CR11 publication-title: Current Opinion in Molecular Therapeutics – volume: 5 start-page: 172 year: 2003 ident: 2591_CR5 publication-title: Genetics in Medicine doi: 10.1097/01.GIM.0000068986.03217.BB – volume: 84 start-page: 591 year: 1989 ident: 2591_CR34 publication-title: British Journal of Addiction doi: 10.1111/j.1360-0443.1989.tb03474.x – volume: 57 start-page: 382 year: 2006 ident: 2591_CR22 publication-title: Psychiatric Services doi: 10.1176/appi.ps.57.3.382 – volume: 335 start-page: 37 issue: 7609 year: 2007 ident: 2591_CR31 publication-title: British Medical Journal doi: 10.1136/bmj.39252.591806.47 – volume: 280 start-page: 32618 year: 2005 ident: 2591_CR13 publication-title: J Biol Chem doi: 10.1074/jbc.M504942200 – volume: 102 start-page: 809 year: 2007 ident: 2591_CR26 publication-title: Addiction doi: 10.1111/j.1360-0443.2007.01791.x – volume: 98 start-page: 23 year: 2003 ident: 2591_CR8 publication-title: Addiction doi: 10.1046/j.1360-0443.2003.00295.x – volume: 7 start-page: 353 year: 2007 ident: 2591_CR18 publication-title: The Pharmacogenomics Journal doi: 10.1038/sj.tpj.6500432 – volume: 422 start-page: 835 issue: 6934 year: 2003 ident: 2591_CR4 publication-title: Nature doi: 10.1038/nature01626 – volume: 11 start-page: 521 year: 2002 ident: 2591_CR24 publication-title: Cancer Epidemiology, Biomarkers & Prevention – volume: 25 start-page: 678 year: 2010 ident: 2591_CR2 publication-title: Health Education Research doi: 10.1093/her/cyp069 – volume: 6 start-page: 211 year: 2005 ident: 2591_CR12 publication-title: Pharmacogenomics doi: 10.1517/14622416.6.3.211 – volume: 5 start-page: 13 year: 2003 ident: 2591_CR39 publication-title: Nicotine &Tobacco Research doi: 10.1080/1462220031000070552 – volume: 62 start-page: 898 year: 2007 ident: 2591_CR37 publication-title: Thorax doi: 10.1136/thx.2006.071837 – ident: 2591_CR32 doi: 10.1002/14651858.CD000146.pub2 – ident: 2591_CR33 doi: 10.1002/14651858.CD000146.pub3 – volume: 25 start-page: 373 year: 2002 ident: 2591_CR29 publication-title: J Behav Med doi: 10.1023/A:1015818532390 |
| SSID | ssj0017852 |
| Score | 2.079497 |
| Snippet | Background
The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication... The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication may... Background The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation medication... Abstract Background: The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation... Abstract Background The behavioural impact of pharmacogenomics is untested; informing smokers of genetic test results for responsiveness to smoking cessation... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 680 |
| SubjectTerms | Adult Biostatistics Biotechnology industry College campuses Communication Deoxyribonucleic acid DNA England Environmental Health Epidemiology Ganglionic Stimulants - administration & dosage Genetic aspects Genetic screening Genetic testing Genotype Genotype & phenotype Health care Health psychology Health sciences Humans Medical research Medicine Medicine & Public Health Molecular Targeted Therapy Nicotine Nicotine - administration & dosage No confidence motions & votes Patient Compliance Prescriptions Preventive medicine Primary care Public Health Receptors, Opioid, mu - genetics Research Design Smoking Smoking - drug therapy Smoking Cessation Smoking cessation products Smoking cessation programs State Medicine Study Protocol Surveys and Questionnaires Vaccine |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYl9FAoJX27SYsOhdKC2bVk65FbWhp6CjmkkJuw9SCBYAevN9D_0x_aGcl21iltL70siyRrLc3sPKSZbwh573VouEeUT3AG8lIKkes62NyH4MqGW81CHYtNyNNTdXGhz3ZKfWFMWIIHThu3Yrxmlkkwy2tbalCnjavLsgrw4zCdcyh9weqZnKnx_kCqWGunANGbs7JS0wWlEqu5DSWQQDjIHYUUcft_l8476ul-6OS9-9Oolk72yZPRnqTHaR1PyQPfPiOP02EcTTlGz8nPc2QzetZ3QweEP6IxUIAiPisewdKhoxhI2vUUw2JBjjTY3QXaAp8MYIfS3sfgLTxKpCll68cRrSkoOtcBp3hHx5j3a_gaK4HQOl4n40QpExPns7vpKHR7Ax-1u0wZhy_I95Ov51--5WN5htyCFzLkwYq1rIXlBceaV83aBu8Lu1ZSiyCCq3SQ4G0Fx0URKscbMO1CozA3V7igHX9J9tqu9a8JrdY-KLA2vNdFWTGvWGMDC75yAcF_qoysJhoZO2KXYwmNaxN9GCUMUtUgVbEFqJqRj_MTNwm34y9jPyPZ53GIuB0bgA_NyIfmX3yYkQ_INAblAryarcf0BlggImyZY1ZyrpWueEYOFyOBSnbRfTCxnRnlycZo2BzNlWQZoXMvPoghcq3vthujwDAVYLzLjLxKPDovCNx6wUpRZkQuuHex4mVPe3UZscbBWhFcwhZ9mvj87qX-tJ9v_sd-HpBHMVADT_D1Idkb-q1_Sx7a2-Fq07-L__ZfABNbYA priority: 102 providerName: Directory of Open Access Journals – databaseName: Engineering Database dbid: M7S link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagcEBCvKGhBfmAhECKdmMnfvSCCqLiVFWiSL1ZiR-0UpUs2Wwl_g8_lBnnwaaIXrisVrETxc7n8dj-5htC3ngdKu5R5RMWA2kuhUh1GWzqQ3B5xa1moYzJJuTxsTo70ycDN2c90CpHmxgNtWss7pEvNExGmivJPqx-pJg0Cg9Xhwwat8kdFElgkbn3dTpEkKpg48mkEosM7HDK8iLKmQrUgdyaiaJg_99meWteus6ZvHZwGuejo4f_2ZJH5MHgiNLDHjmPyS1fPyH3-1082gcnPSW_ThGf9KRtugYQc0Ajw4CisCvu3dKuochAbVqKfFowQBUWN4HWALAOHFja-sj6wj1I2sd6_TygJYUZ0jUAMe_oQJa_hL8xhQgt4zk0PqgP4cTn2e04FrpZwU_pzvtQxWfk29Hn009f0iGvQ2ph-dKlwYqlLIXlGcdkWdXSBu8zu1RSiyCCK3SQsEwLjossFI5X4BOGSmFQr3BBO_6c7NRN7XcJLZY-KOhP73WWF8wrVtnAgi9cQNWgIiGL8RsbO4ieY-6NSxMXP0oYRIVBVOAVQEVC3k13rHrBjxvqfkTYTPVQqjteaNrvZhj5hvGSWSZhXVnaXIM_WLkyz4sAowfGg3MJeYugM2hQ4NVsOcRFQANRmsscspxzrXTBE7I_qwlfyc6K90a8mcEQrc0EtoTQqRRvRG5d7ZvN2ijwaAV4_TIhL3qMTw1i2VKwXOQJkTP0z1o8L6kvzqNIObg5gkvoovfjOPnzUv_qz5c3tmCP3IvUDdzT1_tkp2s3_hW5a6-6i3X7Og793xDDZVg priority: 102 providerName: ProQuest |
| Title | Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence |
| URI | https://link.springer.com/article/10.1186/1471-2458-10-680 https://www.ncbi.nlm.nih.gov/pubmed/21062464 https://www.proquest.com/docview/902193872 https://www.proquest.com/docview/815965337 https://pubmed.ncbi.nlm.nih.gov/PMC2996370 https://doaj.org/article/23a2c27996ac49399bda445febeffddd |
| Volume | 10 |
| WOSCitedRecordID | wos000284893300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: M7S dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: PATMY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3batRAdKitiCBeatXYusyDIAqhm5lkLn1rS4s-dFnaKutTSOZiCyUp2V3B__FDPWeSrE29gL4MIXNhLuecOfch5LXTvuQOs3yCMBCnUohYF97Eznubltxo5ovw2IScTNRspqdrhPWxMMHbvTdJBkod0FqJ3QTIaMzSLGQjFQrE9A247BQi4-nZp5XlQKqM9ebI3_QaXD8hS_-vtPjGZXTbUfKWtTRcQseP_mf6j8nDjuWk-y2MPCFrrtok9046o_omedCq7mgbkfSUfD9HoKTTpl7UACZ7NLgVUMzmigpbuqgpup3WDUUnWqA6JVbXnlYAVQsYkjYuuHqh4pG2AV7f9mhB4Vq0NcCVs7TzkL-Cz_BuCC2C8RkHauM2cTxzM3iFLq-hKOxFG5-4RT4eH50fvo-7xxxiAzLLIvZGjGUhDE84vpBVjo13LjFjJbXwwttMewmymbdcJD6zvARG0JcKI3mF9dryZ2S9qiv3gtBs7LwC3sQ5naQZc4qVxjPvMusxVVAWkd3-jHPTZTrHBzeu8iDxKJHjYeR4GPgHDiMib1c9rtssH39pe4Bgs2qH-bnDj7r5knfonjNeMMMkCJOFSTUwgaUt0jTzgDKABNZG5A0CXY5UBKZmii4YAhaI-bjyfZZyrpXOeER2Bi3hlMygersH27yjPvNcw-ZoriSLCF3VYkd0qKtcvZznCthYAay-jMjzFsZXC2LJWLBUpBGRA-gfrHhYU11ehMzkwNsILmGL3vU48HNSf9rPl__SeJvcD-4bqNfXO2R90SzdK3LXfF1czpsRuSNnMpQKSnWYjMjGwdFkejoKqpYROvaewb_ph5Pp51GgGz8ALl5lJA |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R1Za9RAeKhVUBDvI7bqPCiiEHYzk8xkCiL1KC2tSx9W2Lc0mcMWSrLuZpX-H1_9j37f5HC3Yt_64EsImYPMzHfOdxHywipXcItZPkEZCGMpRKhyp0PrnIkLrhVzuS82IUejdDJRh2vkVxcLg26VHU30hNpUGu_IBwqYkeKpZO-m30IsGoXG1a6CRgMV-_bsB2hs87d7H-F4XzK282n8YTdsiwqEGmTnOnRaDGUuNI84VmoqhtpZG-lhKpVwwplEOQk6gjNcRC4xvACBxBUpRpQK45ThMO8VchXGSvQgk5Nev8M696yzhKZiEAHdD1mc-PSpAvNOLnE-XyDgbzawxAfP-2ieM9R6_rdz-z_buTvkVito0-0GM-6SNVveIzebW0raBF_dJz_HiH_0cFbVFWDEFvUeFBQT1-LdNK0rih621YyivzAQ2AKbK0dLQKAaBHQ6s96rDe9YaRPLdrZFcwoSgKkAhayhbTDAKbz6Eik093Z2nKgJUcX59HKcDl1M4ZGb4yYU8wH5cikb9ZCsl1VpHxOaDK1L4fysVVGcMJuyQjvmbGIcZkVKAjLoYCrTbVJ3rC1ymnnlLhUZQmGGUIhfAAoD8rofMW0SmlzQ9z2Cad8PU5H7D9Xsa9ZStozxnGkmQW_OdaxA3i1MHseJA-oA-G5MQF4hkGdIMOHXdN7GfcACMfVYts1izlWqEh6QzZWecEp6pXmjg--sJbTzrAfugNC-FQei72Bpq8U8S0FiF6DVyIA8anCqXxCLhoLFIg6IXMG2lRWvtpQnxz4JO4hxgkvYojcdXv75qX_t55MLV_CcXN8dfz7IDvZG-xvkhndTQfuF2iTr9Wxhn5Jr-nt9Mp8982SHkqPLxtbfT5vCIQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3ri9QwEA9yyiHIqefj6p2aD4IolN0mbZrct_OxKOqy4Cn3LbR5eAdHu3S7gv-Pf6gzabtezweIX0ppHjTJZDKTmfkNIU-c8iV3iPIJykCc5kLEqvAmdt7btORGMV-EZBP5fC5PTtSiv3BbDd7ug0myi2lAlKaqnSyt77a4FJMEWGrM0iwgkwoJKvvVFFMGobb-8fPGipDLjA2myd-0Gh1FAbH_V7584WC67DR5yXIaDqTZzf8dyi2y04ui9Kijndvkiqt2yfaH3ti-S250V3q0i1S6Q74fI7HSRVO3NZDPIQ3uBhRRXvEil7Y1RXfUuqHoXAvcqMTi2tMKqK2FLmnjggsYXkjSLvDr2yEtKByXtgZ6c5b2nvPn8BryidAiGKWxoy6eE_szF4Na6HoJj8KednGLd8mn2evjl2_iPslDbECXaWNvxDQvhOEJx8xZ5dR45xIzlbkSXnibKZ-DzuYtF4nPLC9BQPSlxAhfYb2y_B7ZqurK7RGaTZ2XILM4p5I0Y06y0njmXWY9QghlEZkM661Nj4COiTjOddCEpNC4GBoXA7_AYkTk2abFskP_-EvdF0hCm3qI2x0-1M0X3bMBzXjBDMtBySxMqkA4LG2RppmHrQSbw9qIPEUC1Mhd4NdM0QdJwAARp0sfsZRzJVXGI3IwqgmrZEbF-wMJ654rrbSCyVFc5iwidFOKDdHRrnL1eqUliLcCVIA8Ivc7et8MiCVTwVKRRiQf7YTRiMcl1dlpQCwHmUfwHKbo-bAffv7Un-bzwb9Ufky2F69m-v3b-bt9cj14eODVvzogW22zdg_JNfO1PVs1jwKD-AFL2GkX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trial+Protocol%3A+Using+genotype+to+tailor+prescribing+of+nicotine+replacement+therapy%3A+a+randomised+controlled+trial+assessing+impact+of+communication+upon+adherence&rft.jtitle=BMC+public+health&rft.au=Marteau%2C+Theresa+M&rft.au=Munaf%C3%B2%2C+Marcus+R&rft.au=Aveyard%2C+Paul&rft.au=Hill%2C+Chloe&rft.date=2010-11-09&rft.pub=BioMed+Central&rft.eissn=1471-2458&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2F1471-2458-10-680&rft.externalDocID=10_1186_1471_2458_10_680 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |